Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

10.31
+0.46004.67%
Volume:1.81M
Turnover:18.12M
Market Cap:1.47B
PE:-2.66
High:10.31
Open:9.66
Low:9.57
Close:9.85
Loading ...

Stifel Nicolaus Sticks to Their Buy Rating for Dyne Therapeutics (DYN)

TIPRANKS
·
31 Jul

Dyne Therapeutics: Strategic Advancements and Financial Stability Drive Buy Rating

TIPRANKS
·
30 Jul

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Benzinga
·
30 Jul

Dyne Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
29 Jul

RBC Trims Price Target on Dyne Therapeutics to $23 From $25, Keeps Outperform, Speculative Risk

MT Newswires Live
·
29 Jul

U.S. RESEARCH ROUNDUP-Blackline, Cadence Design Systems, Coinbase Global

Reuters
·
29 Jul

Dyne Therapeutics Inc : Chardan Capital Markets Cuts Target Price to $38 From $50

THOMSON REUTERS
·
29 Jul

Chardan Capital Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

TIPRANKS
·
29 Jul

Dyne Therapeutics Q2 EPS $(0.97), Inline

Benzinga
·
29 Jul

Dyne Therapeutics Q2 2025: Reports R&D Expenses Rise to $99.2M from $62.3M in Q2 2024, Cash Position Bolstered by $215.2M Offering

Reuters
·
29 Jul

Dyne Therapeutics Secures Breakthrough Therapy Designation from FDA for DYNE-101 in Treatment of Myotonic Dystrophy Type 1

Reuters
·
29 Jul

Dyne Therapeutics Inc - Extends Cash Runway Into Q3 2027

THOMSON REUTERS
·
29 Jul

Dyne Therapeutics Q2 Operating Expenses USD 115.791 Million

THOMSON REUTERS
·
29 Jul

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire
·
29 Jul

Satellos Bioscience Inc. Appoints Dr. Wildon Farwell as New Chief Medical Officer, Succeeding Dr. Jordan Dubow

Reuters
·
16 Jul

Dyne Therapeutics CEO buys $911K in common stock

TIPRANKS
·
16 Jul

John Cox, CEO & President, Reports Acquisition of Common Shares in Dyne Therapeutics Inc

Reuters
·
16 Jul

J.P. Morgan Keeps Their Hold Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
16 Jul

Dyne Therapeutics Is Maintained at Neutral by JP Morgan

Dow Jones
·
16 Jul

Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI

TIPRANKS
·
12 Jul